When and how to combine antiplatelet agents and anticoagulant?
|
|
- Josephine Sims
- 5 years ago
- Views:
Transcription
1 When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium
2 Introduction Anticoagulation platelet inhibition ATRIAL FIBRILLATION the combination of Aspirin and Clopidogrel is not effective as Warfarin in patients with AF From The ACTIVE Writing Group on behalf of the ACTIVE Investigators Lancet 2006; 367: STENTING the combination of Aspirin and thienopyridine is more effective than Warfarin in patients with coronary stents From Leon et al., NEJM 1998;339:
3 Introduction Anticoagulation platelet inhibition ATRIAL FIBRILLATION the combination of Aspirin and Clopidogrel is not effective as Warfarin in patients with AF Risk of Stroke (%) From The ACTIVE Writing Group on behalf of the ACTIVE Investigators Lancet 2006; 367: ACTIVE W
4 Introduction Anticoagulation platelet inhibition STENTING the combination of Aspirin and thienopyridine is more effective than Warfarin in patients with coronary stents Death, TVR, stent thrombosis or MI (%) days STARS from Leon et al., NEJM 1998;339:
5 Introduction Anticoagulation platelet inhibition BEYOND STENTS, ACUTE CORONARY SYNDROMES the combination of Aspirin and thienopyridine is more effective than Aspirin alone CV Death, Non Fatal Myocardial Infarction or Stroke Cumulative Hazard Rate Placebo Clopidogrel (Plavix ) Loading dose 300 mg 75 mg per day from CURE, NEJM 2001:345; CURE Placebo Clopidogrel Months of Follow-up
6 Introduction Anticoagulation platelet inhibition Combination of anticoagulation and (D)APT Bleeding? DAPT Anticoagulation ACS - Stenting AF + stent Atrial fibrillation New P2Y 12 inhibitors? (N)OAC
7 Introduction Anticoagulation platelet inhibition Combination of anticoagulation and (D)APT DAPT Anticoagulation ACS - Stenting Bleeding?
8 Prolonged anticoagulation post-acs Persistent thrombin generation post-acs From Merlini et al, Circulation. 1994;90:61-68.
9 Prolonged anticoagulation post-acs Secondary prevention good compliers (> 70 % at 35 d) poor compliers (<70 % at 35 d) 25 P = P = 0.16 CV death, MI, stroke (%) P = 0.02 P = standard OAC CV death, MI, stroke, Rehospitalisation (%) standard AOC 0 good compliers poor compliers 0 good compliers Poor compliers good compliance is associated with a reduction in major ischemic cardiovascular events OASIS-2 From OASIS investigators JACC 2001;37:
10 Prolonged anticoagulation post-acs PCI Secondary prevention in-hospital follow-up 0-4 to 8 days from hospital discharge P2Y12 inhibitors! Anti-coagulant?
11 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban phase II trial Features Rivaroxaban Apixaban Dabigatran etexilate Acronym ATLAS APRAISE REDEEM n STEMI/NSTEMI (%) 52/ / /40 Dual PLT inhibition (%) Duration (months) Dosage BID Safety outcome Dose-dependent increase in bleeding complications Based on De Caterina et al. JACC 2012;59:
12 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban phase II trial dose escalation 3576 patients with a recent ACS stabilised 1-7 d after index event treat with thienopyridine? Stratum 1 no randomisation Stratum 2 yes randomisation Rivaroxaban placebo Rivaroxaban placebo follow-up 6 months from Mega JL et al., Lancet 2009;374:29-38
13 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban increased risk of bleeding from Mega JL et al., Lancet 2009;374:29-38
14 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban phase III trial patients with a recent ACS stabilised 1-7 d after index event (STEMI, NSTEMI, UA) ASA mg/d with thienopyridine (90 %) Placebo Rivaroxaban 2.5 mg 2x/d Rivaroxaban 5 mg 2x/d Efficacy: death, MI, stroke Primary endpoints Safety: TIMI major bleeding not associated with CABG Rivaroxaban for AF = 20 mg 1x/d (15 mg 1x/d) from Mega JL et al., NEJM 2012;366:9-19
15 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban Death / MI / Stroke (%) % 8.9 % HR 0.84 ( ) P = NNT Months after Randomization ATLAS ACS 2 TIMI 51 from Mega JL et al., NEJM 2012;366:9-19
16 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban % Stent thrombosis (%) ARC definite, probable, possible % HR 0.69 ( ) P = 0.02 Months after Randomization ATLAS ACS 2 TIMI 51 from Mega JL et al., NEJM 2012;366:9-19
17 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban 12 CV death, MI, stroke (%) 8 4 P = % 9.1 % CV death (%) P = % 2.7 % Months after Randomization Months after Randomization ATLAS ACS 2 TIMI 51 from Mega JL et al., NEJM 2012;366:9-19
18 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban Rivaroxaban 2.5 mg 2x/d Rivaroxaban 5 mg 2x/d Placebo TIMI major bleeding (non CABG) 1.8 % 2.4 % 0.6 % P value versus placebo < < TIMI bleeding requiring med. attention 12.9 % 16.2 % 7.5 % P value versus placebo < < Intracranial hemorrhage 0.4 % 0.7 % 0.2 % P value versus placebo Fatal bleeding 0.1 % 0.4 % 0.2 % P value versus placebo ATLAS ACS 2 TIMI 51 from Mega JL et al., NEJM 2012;366:9-19
19 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban Rivaroxaban Low and high dose expression of inflammatory mediators In apoe-deficient mice from Zhouet al., Mediators of inflammation 2011
20 Prolonged anticoagulation post-acs Secondary prevention - Apixaban Apixaban 5 mg 2x/d Apixaban for AF = 5 mg 2x/d Probability of CV death, MI, stroke Months after Randomization APPRAISE 2 from Alexander et al., NEJM 2011;365:
21 Prolonged anticoagulation post-acs Secondary prevention - Apixaban Apixaban 5 mg 2x/d Apixaban for AF = 5 mg 2x/d Probability of TIMI major bleeding Months after Randomization Trial prematurely terminated because of an increase in major bleeding events APPRAISE 2 from Alexander et al., NEJM 2011;365:
22 Prolonged anticoagulation post-acs Anticoagulation versus Aspirin Death, MI, stroke Bleeding Events (%) None ASA ASA + clopidogrel ASA + Prasugrel ASA + Ticagrelor ASA + Clopidogrel + Rivaroxaban
23 Prolonged anticoagulation post-acs Anticoagulation versus Aspirin? 3037 patients randomized after having been started on DAPT At least Up to 48 hours 10 days Rivaroxaban 2.5mg bid ACS Event STEMI* Non-STEMI UA Clopidogrel + ASA or Ticagrelor + ASA Randomize + pre-randomization P2Y12 inhibitor* >6 months duration of therapy ASA 100mg + pre-randomization P2Y12 inhibitor* outcomes **Ticagrelor 90mg bid or Clopidogrel 75mg daily Primary: TIMI major + minor + bleeding requiring medical attention up to day 390. Exploratory ischaemic endpoints included the composite of cardiovascular death, myocardial infarction, stroke, or definite stent thrombosis; all-cause death; GEMINI - ACS from Ohman et al., Lancet 2017;in press
24 Prolonged anticoagulation post-acs Anticoagulation versus Aspirin TIMI non-cabg clinically significant bleeding (%) days GEMINI - ACS from Ohman et al., Lancet 2017;in press
25 Combination in Afib patients The problem Combination of anticoagulation and (D)APT ACS - Stenting AF + stent Atrial fibrillation New P2Y 12 inhibitors? NOAC
26 Combination in Afib patients Triple therapy double therapy Combination of anticoagulation and (D)APT? Gold Standard : Aspirin + Clopidogrel + AVK? DAPT 573 patients with long-term indication for oral anticoagulation treatment (until at least 1 year after the study), undergoing PCI PCI - ACS % - DES 65 % Anticoagulation AF 70 % Randomize Double therapy (284) Clopidogrel VKA Triple therapy (289) ASA Clopidogrel VKA WOEST From De Wilde et al., Lancet 2013; 381:
27 Combination in Afib patients Triple therapy double therapy Combination of anticoagulation and (D)APT Any bleeding (%) death, MI, stroke, target-vessel revascularisation, and stent thrombosis (%) Use of clopidogrel without aspirin was associated with a significant reduction in bleeding complications and no increase in the rate of thrombotic events WOEST From De Wilde et al., Lancet 2013; 381:
28 Combination in Afib patients Guidelines how? Combination of anticoagulation and (D)APT - Guidelines From Kirchhof et al., European Heart Journal (2016) 37,
29 Combination in Afib patients Guidelines how? Combination of anticoagulation and (D)APT - Guidelines From Kirchhof et al., European Heart Journal (2016) 37,
30 Combination in Afib patients Guidelines how? Combination of anticoagulation and (D)APT - Guidelines Short period of triple therapy (OAC, aspirin, clopidogrel) is recommended, followed by a period of dual therapy (OAC plus a single antiplatelet) The use of prasugrel or ticagrelor as part of triple therapy should be avoided unless there is a clear need for these agents (e.g. stent thrombosis on aspirin plus clopidogrel), given the lack of evidence and the greater risk of major bleeding compared with clopidogrel. The dose intensity of OAC should be carefully monitored with a target INR of in patients treated with VKA (with the exception of individuals with mechanical prosthetic valves in the mitral position). The lowest dose effective of (N)OAC for stroke prevention in AF should be considered. Rivaroxaban 15 mg Apixaban 2.5 mg Dabigatran 110 mg Gastric protection with a proton pump inhibitor is recommended From Kirchhof et al., European Heart Journal (2016) 37,
31 Combination in Afib patients Afib trial - Dabigatran Combination of (N)OAC and (D)APT Dabigatran etexilate 110 mg BID was noninferior to warfarin in reducing stroke and systemic embolism, whether patients received antiplatelets RE-LY From Dans et al., Circulation. 2013;127:
32 Combination in Afib patients Afib trial - Dabigatran Combination of (N)OAC and (D)APT RE-LY From Dans et al., Circulation. 2013;127: Events rate (%/year) In the time-dependent analysis, concomitant use of a single antiplatelet increased the risk of major bleeding. Dual antiplatelet increased this even more. The absolute risks were lowest on dabigatran 110 mg BID in comparison with dabigatran 150 mg BID or warfarin.
33 Combination in Afib patients (N)OAC prospective data? Combination of (N)OAC and (D)APT 2100 patients with non-valvular atrial fibrillation undergoing PCI (coronary stenting) No prior stroke/tia, GI bleeding, CrCl < 30 ml/min Randomize 1, 6 or 12 months Pre-randomization choice AVK Clopidogrel 75 mg qd Aspirin mg qd Rivaroxaban 2.5 mg bid Clopidogrel 75 mg qd Aspirin 75 mg qd Rivaroxaban 15 mg qd AVK Rivaroxaban 15 mg qd Clopidogrel 75 mg qd Aspirin mg qd Aspirin mg qd outcomes Triple therapy ATLAS like Primary: TIMI major + minor + bleeding requiring medical attention Secondary: CV death, MI, stroke WOEST like
34 Combination in Afib patients (N)OAC prospective data? Combination of (N)OAC and (D)APT CumulativeIncidenceofClinically SignificantBleeding(%) NNT 11 to 12 VKA + DAPT Riva + DAPT Riva + P2Y 12 days PIONEER AF-PCI From Gibson et al., NEJM 2016;375:
35 Combination in Afib patients (N)OAC prospective data? Combination of (N)OAC and (D)APT CumulativeIncidenceofaMajorAdverse CardiovascularEvent(%) No change in stroke Riva + P2Y 12 VKA + DAPT Riva + DAPT days PIONEER AF-PCI From Gibson et al., NEJM 2016;375:
36 Combination in Afib patients (N)OAC prospective data? Combination of (N)OAC and (D)APT From Gibson et al., NEJM 2016;375: PIONEER AF-PCI From Gibson et al., Circulation. 2017;135:
37 Combination in Afib patients (N)OAC prospective data? Combination of (N)OAC and (D)APT rehospitalisation(%) days PIONEER AF-PCI From Gibson et al., Circulation. 2017;135:
38 Conclusion Efficacy - safety balance ATRIAL FIBRILLATION PCI Double therapy Asa? Clopidogrel The lowest dose effective of (N)OAC for stroke prevention ACS PCI secondary prevention DAPT using new P2Y12 inhibitors Low dose of Rivaroxaban (without ASA?)
39 Introduction Platelets, coagulation cascade and thrombus Coagulation cascade Collagen + other mediators Platelets Anticoagulants Xa Thromboxane ADP Antiplatelets Inflammation Cellular proliferation Thrombin Thrombin Activated platelet Fibrinogen GPIIb/IIIa Fibrin Platelet aggregation Clot
40 Prolonged anticoagulation post-acs Secondary prevention - Rivaroxaban 6 All Placebo (n = 1160) 5.5% Death / MI / Stroke (%) 4 2 All Rivaroxaban (n = 2331) 3.9% HR 0.69 ( ) P = Days After Randomization 180 ATLAS-TIMI 46 from Mega JL et al., Lancet 2009;374:29-38
Which drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationChanging Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events Deepak L. Bhatt, MD, MPH Executive Director Interventional Cardiovascular Programs Brigham and Women s Hospital
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationRobert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
Managing Atrial Fibrillation and ACS/PCI Applying New Evidence to Clinical Practice Dual Anti-Thrombotic Therapy in Acute Coronary Syndromes (ACS) and Afib + PCI/ACS Patients Robert C. Welsh, MD, FRCPC
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationDisclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation
1:15 2:15 PM Challenges in Anticoagulation SPEAKER Nasser Lakkis, MD, FACC, FSCAI Presenter Disclosure Information The following relationships exist related to this presentation: Nasser Lakkis, MD, FACC,
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationPaolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia
Anticoagulanti e mono-antiaggregazione: a chi, quali e per quanto tempo Paolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia Anticoagulazione: Bologna,
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands
DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands RECENT DEVELOPMENTS Better anti-platelet agents: Prasugrel and Ticagrelor to replace
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationDoes COMPASS Change Practice?
Does COMPASS Change Practice? C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division Chairman, PERFUSE Study Group Founder,
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationThe Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationEliquis and plavix combination therapy
Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationAntiplatelet Therapy in Patients on Anticoagulation
Antiplatelet Therapy in Patients on Anticoagulation Ziad A Ali MD DPhil Cardiovascular Research Foundation Columbia University New York, Medical NY Center Cardiovascular Research Foundation Disclosure
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationΣτεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
More informationUPDATES FROM THE 2018 ANTIPLATELET GUIDELINES
UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationRe- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease
Re- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease Robert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
More informationByeong-Keuk Kim, M.D. Ph D. Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea
Byeong-Keuk Kim, M.D. Ph D Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea CASE, M/64 C.C; Recently aggravated chest discomfort for 3 days
More informationNews Release. For UK Media
News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationOptimal Duration of Dual Anti- Platelet Therapy. December 19, 2015
Optimal Duration of Dual Anti- Platelet Therapy December 19, 2015 John S. MacGregor, M.D., Ph.D. Professor of Medicine University of California San Francisco Source: The New Yorker 1 Optimal Duration of
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationAfter acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationDISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM
Rational Use of Antiplatelet Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University What I am Talking About 1. Current
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationDays
Post ACS Care 2013 Clinical dilemmas Christopher Granger, MD Professor of Medicine Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationThe Great debate: thrombocardiology post-compass
The Great debate: thrombocardiology post-compass Anticoagulation should replace antiplatelets in CAD prevention - CON Jean-Philippe COLLET Jean-philippe.collet@psl.aphp.fr Sorbonne Université_Action Study
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationThrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs
Thrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs David J. Moliterno, MD Professor and Chairman Department of Internal Medicine The University of Kentucky Linda and Jack Gill Heart Institute
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationSCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding
More informationPharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO
Pharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Disclosures None Risk of
More informationQuoi de neuf en cardio-gériatrie? Pr Olivier Hanon Hôpital Broca, Paris
Quoi de neuf en cardio-gériatrie? Pr Olivier Hanon Hôpital Broca, Paris Déclaration de relations professionnelles et liens d intérêt Novartis, Daiichi-Sankyo, Boehringer-Ingelheim, Bayer, BMS, Pfizer,
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationA New Era for NOACs: What Does the Future Hold? CME
This article is a CME certified activity. To earn credit for this activity visit: http://www.medscape.org/viewarticle/884772 www.medscape.org A New Era for NOACs: What Does the Future Hold? CME Manesh
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationAdditional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationCURRENT OPINION. European Heart Journal (2014) 35, doi: /eurheartj/ehu298
European Heart Journal (2014) 35, 3155 3179 doi:10.1093/eurheartj/ehu298 CURRENT OPINION Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationDisclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationRivaroxaban (Xarelto ) in patients following acute coronary syndrome with raised biomarkers. Dr Luke Roberts Senior Medical Advisor Bayer PLC
Rivaroxaban (Xarelto ) in patients following acute coronary syndrome with raised biomarkers Dr Luke Roberts Senior Medical Advisor Bayer PLC Date of prep: Jan 2015 Conflicts of interest: Salaried employee
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationRobert Storey. Sheffield, United Kingdom
Breakthrough Antiplatelets and Anticoagulants: Focus on brand new drugs Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More information